Alpha 2.0
Login Register
» Authors » T Lasho

T Lasho

Explore the profile of T Lasho including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 635
Followers 0
Related Specialties
Oncology
Hematology
Top 10 Co-Authors
A Tefferi
A Pardanani
C Finke
W Wu
C A Hanson
R A Mesa
D Zblewski
C Rivera
K Hussein
N Gangat
Published In
Leukemia
Blood Cancer J
Affiliations
Soon will be listed here.
Recent Articles
1.
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson C, Ketterling R, et al.
Blood Cancer J . 2017 Dec; 7(12):662. PMID: 29282357
In a recent International Working Group on Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) study, prior arterial events and hypertension were predictors of subsequent arterial thrombosis whereas prior venous events and...
2.
Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing
Pardanani A, Lasho T, Wassie E, Finke C, Zblewski D, Hanson C, et al.
Leukemia . 2016 Apr; 30(9):1924-6. PMID: 27125206
No abstract available.
3.
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
Padron E, Garcia-Manero G, Patnaik M, Itzykson R, Lasho T, Nazha A, et al.
Blood Cancer J . 2015 Aug; 5:e333. PMID: 26230957
Since its reclassification as a distinct disease entity, clinical research efforts have attempted to establish baseline characteristics and prognostic scoring systems for chronic myelomonocytic leukemia (CMML). Although existing data for...
4.
Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells
Pardanani A, Lasho T, Chen D, Kimlinger T, Finke C, Zblewski D, et al.
Leukemia . 2015 Feb; 29(7):1605-8. PMID: 25640886
No abstract available.
5.
Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia
Kosmider O, Itzykson R, Chesnais V, Lasho T, Laborde R, Knudson R, et al.
Leukemia . 2013 Jun; 27(9):1946-9. PMID: 23774674
No abstract available.
6.
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, et al.
Leukemia . 2011 Apr; 25(7):1200-2. PMID: 21455215
No abstract available.
7.
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
Pardanani A, Lasho T, Finke C, Oh S, Gotlib J, Tefferi A
Leukemia . 2010 Aug; 24(10):1713-8. PMID: 20724988
LNK mutation analysis was performed in 61 patients with blast-phase myeloproliferative neoplasms (MPN); post-primary myelofibrosis (PMF) in 41, post-polycythemia vera in 11 and post-essential thrombocythemia in 9 patients. Paired chronic-blast...
8.
Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells
Lasho T, Tefferi A, Pardanani A
Leukemia . 2010 May; 24(7):1378-80. PMID: 20485374
No abstract available.
9.
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
Pardanani A, Lasho T, Smith G, Burns C, Fantino E, Tefferi A
Leukemia . 2009 Mar; 23(8):1441-5. PMID: 19295546
Somatic mutations in Janus kinase 2 (JAK2), including JAK2V617F, result in dysregulated JAK-signal transducer and activator transcription (STAT) signaling, which is implicated in myeloproliferative neoplasm (MPN) pathogenesis. CYT387 is an...
10.
5-Azacitidine has limited therapeutic activity in myelofibrosis
Mesa R, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, et al.
Leukemia . 2008 May; 23(1):180-2. PMID: 18509350
No abstract available.